Literature DB >> 17848406

Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis.

Rupal Shroff1, Angela Kerchner, Michelle Maifeld, Edwin J R Van Beek, Dinesh Jagasia, Anuja Dokras.   

Abstract

CONTEXT: Polycystic ovary syndrome (PCOS) is associated with comorbidities that may contribute to increased risk of cardiovascular disease. PCOS is associated with increased risk of metabolic syndrome, dyslipidemia, and diabetes, but it remains unclear whether traditional cardiovascular (CV) risk factors can help predict coronary artery disease in this population.
OBJECTIVE: The objectives of the study were to detect early-onset subclinical coronary atherosclerosis (using coronary artery calcium as a marker) in young women with PCOS, compared with age- and body mass index-matched controls, and to compare traditional CV risk factors and inflammatory markers in the two groups.
DESIGN: This was a prospective case-control study.
SETTING: The study was conducted at a university hospital.
SUBJECTS: Twenty-four obese (body mass index >or= 30 kg/m2) PCOS subjects and 24 obese controls participated. OUTCOME MEASURES: Coronary artery calcium, inflammatory markers (high-sensitivity C-reactive protein, IL-6, TNFalpha, adiponectin, leptin), fasting blood tests (glucose, lipids, insulin), and dual-energy x-ray absorptiometry scan for body fat distribution were measured.
RESULTS: Coronary artery calcium was detected in eight of 24 PCOS subjects (33%) and two of 24 controls (8%) (odds ratio 5.5, 95% confidence interval 1.03, 29.45, P < 0.03). Traditional CV risk factors did not differ significantly between the two groups, nor did markers of inflammation or adiposity, body fat distribution, or metabolic parameters with the exception of significantly lower quantitative insulin sensitivity check index (marker for insulin resistance) in the PCOS group (P < 0.05).
CONCLUSIONS: Young, obese women with PCOS have a high prevalence of early asymptomatic coronary atherosclerosis, compared with obese controls. This increased risk is independent of traditional CV risk factors and novel markers of inflammation. These findings underscore the need to screen and aggressively counsel and treat these women to prevent symptomatic CV disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17848406     DOI: 10.1210/jc.2007-1343

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  54 in total

1.  The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome.

Authors:  Monika Sarkar; Norah Terrault; Caroline C Duwaerts; Phyllis Tien; Marcelle I Cedars; Heather Huddleston
Journal:  Curr Opin Gynecol Obstet       Date:  2018-04-05

2.  Morning Circadian Misalignment Is Associated With Insulin Resistance in Girls With Obesity and Polycystic Ovarian Syndrome.

Authors:  Stacey L Simon; Laura McWhirter; Cecilia Diniz Behn; Kate M Bubar; Jill L Kaar; Laura Pyle; Haseeb Rahat; Yesenia Garcia-Reyes; Anne-Marie Carreau; Kenneth P Wright; Kristen J Nadeau; Melanie Cree-Green
Journal:  J Clin Endocrinol Metab       Date:  2019-08-01       Impact factor: 5.958

Review 3.  Targets to treat metabolic syndrome in polycystic ovary syndrome.

Authors:  Shruthi Mahalingaiah; Evanthia Diamanti-Kandarakis
Journal:  Expert Opin Ther Targets       Date:  2015-10-21       Impact factor: 6.902

4.  Assessing the intersection of cardiovascular disease, venous thromboembolism, and polycystic ovary syndrome.

Authors:  Ekwutosi M Okoroh; Sheree L Boulet; Mary G George; W Craig Hooper
Journal:  Thromb Res       Date:  2015-10-17       Impact factor: 3.944

5.  Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers.

Authors:  Sonali S Patel; Uyen Truong; Martina King; Annie Ferland; Kerrie L Moreau; Jennifer Dorosz; John E Hokanson; Hong Wang; Gregory L Kinney; David M Maahs; Robert H Eckel; Kristen J Nadeau; Melanie Cree-Green
Journal:  Vasc Med       Date:  2017-01-17       Impact factor: 3.239

6.  Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis.

Authors:  Shan Li; Xiamei Huang; Huizhi Zhong; Qiliu Peng; Siyuan Chen; Yantong Xie; Xue Qin; Aiping Qin
Journal:  Tumour Biol       Date:  2014-01-12

7.  Ghrelin is independently associated with anti-mullerian hormone levels in obese but not non-obese women with polycystic ovary syndrome.

Authors:  Margaret C Garin; Samantha F Butts; David B Sarwer; Kelly C Allison; Suneeta Senapati; Anuja Dokras
Journal:  Endocrine       Date:  2016-12-21       Impact factor: 3.633

8.  Hyperandrogenaemia in adolescent girls: origins of abnormal gonadotropin-releasing hormone secretion.

Authors:  C M Burt Solorzano; C R McCartney; S K Blank; K L Knudsen; J C Marshall
Journal:  BJOG       Date:  2010-01       Impact factor: 6.531

9.  Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome.

Authors:  Brooke Rossi; Sara Sukalich; Jennifer Droz; Adam Griffin; Stephen Cook; Aaron Blumkin; David S Guzick; Kathleen M Hoeger
Journal:  J Clin Endocrinol Metab       Date:  2008-09-23       Impact factor: 5.958

10.  Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention.

Authors:  L J Moran; C Meyer; S K Hutchison; S Zoungas; H J Teede
Journal:  J Endocrinol Invest       Date:  2009-10-15       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.